首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
【24h】

In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

机译:在与大肠杆菌或粪便肠球菌耐万古霉素的菌株混合培养物中,用厌氧时间杀灭技术测定曲伐沙星对脆弱拟杆菌的体外活性。

获取原文
获取原文并翻译 | 示例
       

摘要

To determine the efficacy of trovafloxacin as a possible treatment for intra-abdominal abscesses, we have developed an anaerobic time-kill technique using different inocula to study the in vitro killing of Bacteroides fragilis in pure culture or in mixed culture with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium (VREF). With inocula of 5 x 10(5) CFU/ml and trovafloxacin concentrations of /=6.1 (log(10) CFU/ml) was attained with all pure and mixed cultures within 24 h. With inocula of 10(8) CFU/ml, a similar E(max) and a similar concentration to produce 50% of E(max) (EC(50)) for B. fragilis were found in both pure cultures and mixed cultures with E. coli. However, to produce a similar killing of B. fragilis in the mixed cultures with VREF, a 14-fold increase in the concentration of trovafloxacin was required. A vancomycin-susceptible strain of E. faecium and a trovafloxacin-resistant strain of E. coli were also found to confer a similar "protective" effect on B. fragilis against the activity of trovafloxacin. Using inocula of 10(9) CFU/ml, the activity of trovafloxacin was retained for E. coli and B. fragilis and was negligible against VREF. We conclude that this is a useful technique to study the anaerobic killing of mixed cultures in vitro and may be of value in predicting the killing of mixed infections in vivo. The importance of using mixed cultures and not pure cultures is clearly shown by the difference in the killing of B. fragilis in the mixed cultures tested. Trovafloxacin will probably be ineffective in the treatment of infections involving large numbers of enterococci. However, due to its ability to retain activity against large cultures of B. fragilis and E. coli, trovafloxacin could be beneficial in the treatment of intra-abdominal abscesses.
机译:为了确定曲伐沙星可能用于治疗腹腔内脓肿的功效,我们开发了一种无氧时间杀灭技术,使用不同的接种物来研究纯细菌培养物中或与大肠杆菌或大肠杆菌混合培养物中的脆弱拟杆菌的体外杀灭。粪肠球菌耐万古霉素的菌株(VREF)。接种量为5 x 10(5)CFU / ml,曲伐沙星浓度为 / = 6.1(log(10)CFU / ml)在24小时内使用所有纯净和混合培养。在10(8)CFU / ml的接种量下,在纯培养物和混合培养物中均发现了相似的E(max)和相似浓度以产生脆弱型芽孢杆菌的E(max)(EC(50))的50%。大肠杆菌。然而,为了在用VREF的混合培养物中杀灭脆弱的芽孢杆菌,需要将曲伐沙星的浓度提高14倍。还发现了对万古霉素敏感的屎肠球菌菌株和对曲伐沙星耐药的大肠杆菌菌株赋予脆弱类芽孢杆菌类似的“保护”作用,以抵抗曲伐沙星的活性。使用10(9)CFU / ml的接种量,曲伐沙星对大肠杆菌和脆弱型芽孢杆菌的活性得以保留,而对VREF的影响可忽略不计。我们得出的结论是,这是一种在体外研究混合培养物厌氧性杀伤的有用技术,对预测体内混合感染的杀伤性可能具有价值。混合培养物而非纯培养物的重要性已通过测试混合培养物中脆弱脆弱芽孢杆菌的杀灭差异清楚地表明。曲伐沙星可能在治疗涉及大量肠球菌的感染中无效。但是,由于曲伐沙星具有针对脆弱的芽孢杆菌和大肠杆菌的大型培养物保持活性的能力,因此在腹腔内脓肿的治疗中可能是有益的。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号